{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:53:29Z","timestamp":1790916809552,"version":"4.1.0"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":162,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101288","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T03:17:11Z","timestamp":1781752631000},"page":"101288","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Mapping the evidence of stereotactic body radiotherapy combined with systemic therapy in oligometastatic and oligoprogressive non-small cell lung cancer: A visual synthesis of clinical outcomes and toxicity"],"prefix":"10.1016","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-3090-5795","authenticated-orcid":false,"given":"Vasileios","family":"Karagiannis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Tolia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Vomvas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michalis","family":"Mazonakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna-Maria","family":"Shiarli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juha","family":"Saarinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelli-Sofia","family":"N\u00e5hls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Ntaskagiannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgiou","family":"Morfo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antti","family":"Jekunen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2026.101288_bib0001","unstructured":"International Agency for Research on Cancer (IARC). Lung cancer fact sheet: GLOBOCAN 2020 [Internet]. Lyon (France): International Agency for Research on Cancer; 2020 [cited 2025 May 30]. Available from: https:\/\/gco.iarc.fr\/."},{"key":"10.1016\/j.ctarc.2026.101288_bib0002","series-title":"Cancer Facts & Figures 2024","year":"2024"},{"key":"10.1016\/j.ctarc.2026.101288_bib0003","unstructured":"National Cancer Institute (NCI). Surveillance, Epidemiology, and End Results (SEER) Cancer Statistics Review, 1975\u20132016 [Internet]. Bethesda (MD): National Cancer Institute; 2020 [cited 2025 May 30]. Available from: https:\/\/seer.cancer.gov\/csr\/1975_2016\/."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101288_bib0004","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jtho.2015.09.009","article-title":"The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer","volume":"11","author":"Goldstraw","year":"2016","journal-title":"J. Thorac. Oncol"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101288_bib0005","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctarc.2026.101288_bib0006","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.radonc.2020.04.003","article-title":"Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus document","volume":"148","author":"Lievens","year":"2020","journal-title":"Radiother. Oncol."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101288_bib0007","first-page":"e347","article-title":"Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: an ESTRO-ASTRO consensus statement","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101288_bib0008","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.3390\/cancers12041046","article-title":"Oligoprogressive non-small-cell lung cancer under treatment with PD-(L)1 inhibitors","volume":"12","author":"Rheinheimer","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ctarc.2026.101288_bib0009","article-title":"Progression patterns, treatment, and prognosis beyond resistance of responders to immunotherapy in advanced non-small cell lung cancer","volume":"11","author":"Xu","year":"2021","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101288_bib0010","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1158\/2159-8290.CD-20-1726","article-title":"INK4 tumor suppressor proteins mediate resistance to CDK4\/6 kinase inhibitors","volume":"12","author":"Li","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ctarc.2026.101288_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110288","article-title":"Systematic review of the efficacy of stereotactic ablative radiotherapy for oligoprogressive disease in metastatic cancer","volume":"196","author":"Doyle","year":"2024","journal-title":"Radiother. Oncol."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101288_bib0012","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1097\/JS9.0000000000000339","article-title":"Role of local ablative treatment in oligometastatic non-small cell lung cancer: a meta-analysis","volume":"109","author":"Rim","year":"2023","journal-title":"Int. J. Surg."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101288_bib0013","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/S1470-2045(16)30532-0","article-title":"Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study","volume":"17","author":"Gomez","year":"2016","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101288_bib0014","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial","volume":"4","author":"Iyengar","year":"2018","journal-title":"JAMA Oncol."},{"issue":"29","key":"10.1016\/j.ctarc.2026.101288_bib0051","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial","volume":"38","author":"Palma","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101288_bib0015","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s40425-018-0382-2","article-title":"The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)","volume":"6","author":"Brahmer","year":"2018","journal-title":"J. Immunother. Cancer"},{"issue":"10","key":"10.1016\/j.ctarc.2026.101288_bib0016","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1200\/JCO.2013.53.1228","article-title":"Recent clinical advances in lung cancer management","volume":"32","author":"Johnson","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"9893","key":"10.1016\/j.ctarc.2026.101288_bib0017","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(13)61502-0","article-title":"Management of non-small-cell lung cancer: recent developments","volume":"382","author":"Reck","year":"2013","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ctarc.2026.101288_bib0018","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1586\/era.13.47","article-title":"Targeted therapy for non-small-cell lung cancer: past, present and future","volume":"13","author":"Forde","year":"2013","journal-title":"Expert Rev. Anticancer. Ther."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101288_bib0019","doi-asserted-by":"crossref","first-page":"292","DOI":"10.6004\/jnccn.2012.0029","article-title":"Ten years of progress in non-small cell lung cancer","volume":"10","author":"Ettinger","year":"2012","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101288_bib0020","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1200\/JCO.18.00149","article-title":"Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater","volume":"37","author":"Reck","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101288_bib0021","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/jamaoncol.2020.6146","article-title":"Safety and survival rates associated with ablative stereotactic radiotherapy for patients with oligometastatic cancer: a systematic review and meta-analysis","volume":"7","author":"Lehrer","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ctarc.2026.101288_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.115043","article-title":"A new proposal of simplified classification of non-small cell lung cancer oligometastases for easy applicability through systematic literature analysis and meta-analysis validation","volume":"212","author":"Kang","year":"2024","journal-title":"Eur. J. Cancer"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101288_bib0033","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.ijrobp.2024.10.022","article-title":"Phase 2 trial of consolidative stereotactic body radiation therapy in patients with metastatic oncogene-driven non-small cell lung carcinoma treated with tyrosine kinase inhibitors","volume":"121","author":"Keane","year":"2025","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ctarc.2026.101288_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2025.108553","article-title":"ETOP 14-18 CHESS collaborators. Multimodality treatment in synchronous oligometastatic NSCLC: analysis of the ETOP CHESS trial","volume":"204","author":"Guckenberger","year":"2025","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctarc.2026.101288_bib0032","article-title":"Safety and efficacy of consolidative stereotactic radiotherapy for oligo-residual EGFR-mutant non-small cell lung cancer after first-line third-generation EGFR-tyrosine kinase inhibitors: a single-arm, phase 2 trial","volume":"76","author":"Zhou","year":"2024","journal-title":"E Clin. Med."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101288_bib0034","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.21037\/tlcr-24-588","article-title":"Efficacy and prognostic factors of stereotactic body radiotherapy combined with immunotherapy for pulmonary oligometastases: a preliminary retrospective cohort study","volume":"13","author":"Piao","year":"2024","journal-title":"Transl. Lung Cancer Res."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101288_bib0023","doi-asserted-by":"crossref","first-page":"465","DOI":"10.21037\/tlcr-23-802","article-title":"Outcomes of extracranial stereotactic body radiation therapy for induced oligometastatic non-small cell lung cancer on novel systemic therapy","volume":"13","author":"Tsur","year":"2024","journal-title":"Transl Lung Cancer Res."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101288_bib0035","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.21037\/tcr-23-2232","article-title":"The analysis of the efficacy and safety of stereotactic body radiotherapy with sequential immune checkpoint inhibitors in the management of oligoprogressive advanced non-small cell lung cancer","volume":"13","author":"Ying","year":"2024","journal-title":"Transl. Cancer Res."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101288_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.cllc.2024.07.009","article-title":"Outcomes analysis of patients receiving local ablative therapy for oligoprogressive metastatic NSCLC under first-line immunotherapy","volume":"25","author":"Huet","year":"2024","journal-title":"Clin. Lung Cancer"},{"issue":"12","key":"10.1016\/j.ctarc.2026.101288_bib0026","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.21037\/tlcr-24-554","article-title":"Radiotherapy for oligoprogressive disease in non-small cell lung cancer treated with pembrolizumab in first-line setting: a retrospective study","volume":"13","author":"Santonja","year":"2024","journal-title":"Transl. Lung Cancer Res."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101288_bib0029","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/jnci\/djac015","article-title":"Randomized trial of first-line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-mutated non-small cell lung cancer","volume":"115","author":"Wang","year":"2023","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ctarc.2026.101288_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.109681","article-title":"EGFR-TKIs plus stereotactic body radiation therapy (SBRT) for stage IV non-small cell lung cancer (NSCLC): a prospective, multicenter, randomized, controlled phase II study","volume":"184","author":"Peng","year":"2023","journal-title":"Radiother. Oncol."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101288_bib0024","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.cllc.2023.08.015","article-title":"Stereotactic body radiation therapy for oligoprogressive and oligorecurrent non-small-cell lung cancer","volume":"24","author":"Ebadi","year":"2023","journal-title":"Clin. Lung Cancer"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101288_bib0031","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/cam4.4894","article-title":"Radiotherapy with continued EGFR-TKIs for oligoprogressive disease in EGFR-mutated non-small cell lung cancer: a real-world study","volume":"12","author":"Hu","year":"2023","journal-title":"Cancer Med."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101288_bib0036","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jtho.2021.08.019","article-title":"A phase 1 trial of concurrent or sequential ipilimumab, nivolumab, and stereotactic body radiotherapy in patients with stage IV NSCLC","volume":"17","author":"Bestvina","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ctarc.2026.101288_bib0025","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.lungcan.2020.12.029","article-title":"Consolidative stereotactic ablative radiotherapy (SABR) to intrapulmonary lesions is associated with prolonged progression-free survival and overall survival in oligometastatic NSCLC patients: a prospective phase 2 study","volume":"152","author":"Blake-Cerda","year":"2021","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101288_bib0037","doi-asserted-by":"crossref","first-page":"184","DOI":"10.21037\/tcr-20-2772","article-title":"Assessing efficacy and safety of stereotactic body radiation therapy for oligometastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) wild type","volume":"10","author":"Hu","year":"2021","journal-title":"Transl. Cancer Res."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101288_bib0049","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101288_bib0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003998","article-title":"Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: long-term results from the STAMPEDE randomised controlled trial","volume":"19","author":"Parker","year":"2022","journal-title":"PLoS Med."},{"issue":"10422","key":"10.1016\/j.ctarc.2026.101288_bib0048","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0140-6736(23)01857-3","article-title":"Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (CURB): an open-label, randomized, controlled phase 2 study","volume":"403","author":"Tsai","year":"2024","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ctarc.2026.101288_bib0046","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin\u2013paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101288_bib0047","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101288_bib0053","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.ctarc.2026.101288_bib0041","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.21.02885","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy as first-line therapy in patients with non\u2013small-cell lung cancer and programmed death ligand-1 tumor proportion score \u22651% in the KEYNOTE-042 study","volume":"41","author":"de Castro G","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101288_bib0042","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non\u2013small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"10.1016\/j.ctarc.2026.101288_bib0043","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced non\u2013squamous non\u2013small\u2013cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101288_bib0054","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1001\/jamaoncol.2015.4921","article-title":"First-line erlotinib therapy until and beyond response evaluation criteria in solid tumors progression in Asian patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer: the ASPIRATION study","volume":"2","author":"Park","year":"2016","journal-title":"JAMA Oncol."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101288_bib0055","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11523-015-0387-4","article-title":"Impact of continuing first-line EGFR tyrosine kinase inhibitor therapy beyond RECIST disease progression in patients with advanced EGFR-mutated non-small-cell lung cancer (NSCLC): retrospective GFPC 04-13 study","volume":"11","author":"Auliac","year":"2016","journal-title":"Target Oncol."},{"issue":"15","key":"10.1016\/j.ctarc.2026.101288_bib0056","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1002\/cncr.29397","article-title":"Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer","volume":"121","author":"Lo","year":"2015","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101288_bib0057","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(16)30624-6","article-title":"Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study","volume":"18","author":"Hellmann","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctarc.2026.101288_bib0058","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1200\/JCO.18.01042","article-title":"First-line nivolumab plus ipilimumab in advanced non-small-cell lung cancer (CheckMate 568): outcomes by programmed death ligand 1 and tumor mutational burden as biomarkers","volume":"37","author":"Ready","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101288_bib0059","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","article-title":"Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer","volume":"346","author":"Schiller","year":"2002","journal-title":"N. Engl. J. Med"},{"issue":"21","key":"10.1016\/j.ctarc.2026.101288_bib0060","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","article-title":"Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer","volume":"26","author":"Scagliotti","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101288_bib0040","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1039157","article-title":"The effect of immunotherapy on oligometastatic non-small cell lung cancer patients by sites of metastasis","volume":"13","author":"Ma","year":"2022","journal-title":"Front. Immunol."},{"issue":"19","key":"10.1016\/j.ctarc.2026.101288_bib0045","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101288_bib0044","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1200\/JCO.20.01605","article-title":"Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: nivolumab versus docetaxel in previously treated non\u2013small-cell lung cancer","volume":"39","author":"Borghaei","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101288_bib0038","article-title":"Outcomes with local therapy and tyrosine kinase inhibition in patients with ALK\/ROS1\/RET-rearranged lung cancers","volume":"6","author":"Hubbeling","year":"2022","journal-title":"CO Precis. Oncol."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101288_bib0052","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1007\/s00432-021-03831-z","article-title":"Stereotactic body radiotherapy to the primary lung lesion improves the survival of the selected patients with non-oligometastatic NSCLC harboring EGFR activating mutation with first-line EGFR-TKIs: a real-world study","volume":"148","author":"Wei","year":"2022","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ctarc.2026.101288_bib0039","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.ijrobp.2024.05.015","article-title":"Local ablative therapy combined with pembrolizumab in patients with synchronous oligometastatic non-small cell lung cancer: a recursive partitioning analysis","volume":"120","author":"Lee","year":"2024","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226001991?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226001991?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:57:00Z","timestamp":1790913420000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226001991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":60,"alternative-id":["S2468294226001991"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101288","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mapping the evidence of stereotactic body radiotherapy combined with systemic therapy in oligometastatic and oligoprogressive non-small cell lung cancer: A visual synthesis of clinical outcomes and toxicity","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101288","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101288"}}